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a b s t r a c t
Diabetes is a high risk factor for dementia. High glucose may be a risk factor for dementia even among
persons without diabetes, and in transgenic animals it has been shown to cause a potentiation of indices
that are pre-symptomatic of Alzheimer0s disease. To further elucidate the underlying mechanisms linking
inﬂammatory events elicited in the brain during oxidative stress and diabetes, we monitored the
activation of mitogen-activated kinsase (MAPKs), c-jun NH2-terminal kinase (JNK), p38 MAP kinases
(p38MAPK), and extracellular activating kinsae1/2 (ERK1/2) and the anti-inﬂammatory effects of the
thioredoxin mimetic (TxM) peptides, Ac-Cys-Pro-Cys-amide (CB3) and Ac-Cys-Gly-Pro-Cys-amide (CB4)
in the brain of male leptin-receptor-deﬁcient Zucker diabetic fatty (ZDF) rats and human neuroblastoma
SH-SY5Y cells. Daily i.p. injection of CB3 to ZDF rats inhibited the phosphorylation of JNK and p38MAPK,
and prevented the expression of thioredoxin-interacting-protein (TXNIP/TBP-2) in ZDF rat brain.
Although plasma glucose/insulin remained high, CB3 also increased the phosphorylation of AMP-
ribose activating kinase (AMPK) and inhibited p70S6K kinase in the brain. Both CB3 and CB4 reversed
apoptosis induced by inhibiting thioredoxin reductase as monitored by decreasing caspase 3 cleavage
and PARP dissociation in SH-SY5Y cells. The decrease in JNK and p38MAPK activity in the absence of a
change in plasma glucose implies a decrease in oxidative or neuroinﬂammatory stress in the ZDF rat
brain. CB3 not only attenuated MAPK phosphorylation and activated AMPK in the brain, but it also
diminished apoptotic markers, most likely acting via the MAPK–AMPK–mTOR pathway. These results
were correlated with CB3 and CB4 inhibiting inﬂammation progression and protection from oxidative
stress induced apoptosis in human neuronal cells. We suggest that by attenuating neuro-inﬂammatory
processes in the brain Trx1 mimetic peptides could become beneﬁcial for preventing neurological
disorders associated with diabetes.
& 2014 The Authors. Published by Elsevier B.V. All rights reserved.
Introduction
Aging patients with Type 2 diabetes (T2D) are at a high risk of
developing cognitive and memory impairments including some of
Alzheimer disease0s (AD) most signiﬁcant symptoms [1]. In recent
years it has become evident that some characteristics of AD are
regulated by insulin-like growth factor signaling cascades [2]. The
greatest risk factor of AD and T2D is age and one of the major
hallmarks of the aging process is oxidative stress. The thioredoxin
reductase–thioredoxin system (TrxR–Trx1) is part of the powerful
enzymatic machinery that maintains the redox balance of the cell
[3,4]. Neuronal Trx1 is decreased in AD brains and Trx1 is oxidized
by the β-amyloid (Aβ) peptide, through an inﬂammatory mediated
apoptotic cycle. Trx1 regulates apoptosis by inhibiting the apoptosis
signal-regulating kinase-1 (ASK1), which activates the JNK and
p38MAPK pathways [5]. Trx1 also prevents apoptosis through asso-
ciation with other proteins like the Trx1-interacting protein-2 (TBP-
2) also called TXNIP or VDUP-1. While TXNIP/TBP-2 binds to the
active Cys residue of Trx1 and inhibits its redox activity, Trx1 itself
binds the non-catalytic region of ASK1 and inhibits its kinase activity
[6–13]. TXNIP/TBP-2 is a member of early response genes involved
in neuronal apoptosis induced by high glucose, oxidative stress, or
Ca2þ . It was shown to regulate the transcription factor c-jun in
cerebellar granule neurons [14]. Neuronal cell death induced by
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ischemic–reperfusion or hyperglycemic–ischemic–reperfusion was
prevented by the down regulation of TXNIP/TBP-2 [15]. The diver-
gent effects of glucose and fatty acids on TXNIP/TBP-2 expression
result in part from their opposing effects on AMP-activated protein
kinase (AMPK) activity. The effects of high glucose on insulin
resistance, which have been attributed to insulin receptor substrate
phosphorylation, are induced through a decrease in AMPK, a
heterotrimeric protein composed of a catalytic subunit (α) and
two regulatory subunits (β and γ) that are activated in anaerobic
conditions [16], [17]. Activation of the AMPK pathway by metformin
treatment normalized impaired cell proliferation and neuroblast
differentiation in the subgranular zone of the hippocampal dentate
gyrus in Zucker diabetic fatty (ZDF) rats [18]. High-glucose levels in
the lateral hypothalamus also decreased the expression of the AMPK
gene [19]. More recently it was demonstrated that activation of
AMPK alleviates high glucose-induced dysfunction of brain micro-
vascular endothelial cells by suppressing the induction of NADPH
oxidase-derived superoxide anions [20]. The loss of islet DNA
binding activity of pancreas duodenum homeobox-1 and insulin
gene expression in the ZDF rat was prevented in animals treated
with troglitazone [21], or N-acetyl cysteine (NAC) [22]. Since NAC
has antioxidant activity, it was hypothesized that glucose toxicity in
the ZDF animal may be explained in part by chronic oxidative stress
[23]. Furthermore, JNK activity, which was elevated by oxidative
stress causing β-cell dysfunction, was overcome by suppression of
the JNK pathway [24]. In liver, muscle and adipose tissues of dietary
and genetic (ob/ob) obesity models, there was a signiﬁcant increase
in total JNK activity, highlighting JNK as a crucial mediator of obesity
and insulin resistance, and a potential target for therapeutics [25]. In
the ovalbumin (OVA)-inhaled mice, a rodent model of asthma,
treatment with NAc-Cys-Pro Cys-amide (CB3), a thioredoxin
mimetic peptide [26,27], prevented reactive oxygen species (ROS)
related damages through inhibition of p38MAPK activation and
prevention of NF-kB nuclear translocation [28]. In the present study
we explored CB3 ability to protect the brain from multiple factors
involved in the oxidative stress pathway associated with diabetes.
We showed that the Trx1 mimetic peptides CB3 known to inhibit
JNK and p38MAPK phosphorylation in ﬁbroblasts [29], neuroendorine
PC12 [26], and INS 832/13 insulinoma cells [27], prevented apoptosis
in human neuroblastoma SH-SY5Y cells. We show that in the
ZDF rat brain, CB3 lowered markers of inﬂammation, reduced
TXNIP/TBP-2 expression, activated AMPK and thereby inhibited the
mTOR–p70S6K pathway. Hence, CB3 could have a potential beneﬁt
for decreasing detrimentaleffects elicited in the brain during chronic
hyperglycemia.
Materials and methods
Reagents
All materials were purchased from Sigma, Jerusalem, if not
otherwise stated; Auranoﬁn (Enzo life sciences, Shoham, Israel),
triethylphosphine (2,3,4,6-tetra-O-acetyl-β-1-D-thiopyranosato-S)
gold(I); thioredoxin mimetic (TXM) peptides TXM-CB3 and -CB4
were custom synthesized by Novetide, Ltd. Haifa; Thinkpeptides,
Oxford, UK, and GL Biochem., Shanghai, China; tissue culture
serum and medium were from Biological Industries, Kibbutz
Beit-Haemek, Israel.
Cells
SH-SY5Y human neuroblastoma cells were kindly provided by
H Soreq H. (Hebrew University of Jerusalem, Israel). The cells were
cultured in DMEM/F12 HAM 1:1 medium supplemented with 10%
fetal bovine serum (FBS) and penicillin–streptomycin, incubated at
37 1C with 5% CO2.
Cell viability
SH-SY5Y cells were seeded in 96-well plates and treated with
5 mM AuF for 30 min, or high glucose, washed and cultured with or
without increasing concentrations of CB3, or CB4, as indicated.
Twenty-four hours later, the cells were ﬁxed with glutaraldehyde
in a ﬁnal concentration of 0.5% for 10 min. Cells were washed
3 times with DDW, dried over night, and washed once with borate
buffer (0.1 M, pH 8.5). The ﬁxed cells were stained with 200 ml of
1% methylene blue in borate buffer for 1 h. After extensive
washing and drying, the color was extracted with 200 ml of 0.1 M
HCl for 1 h at 37 1C. Later cell viability was measured using
spectrophotometer at 630 nm.
Zucker diabetic fatty (ZDF) rat animal study
In this study we used the obese diabetic Zucker rat, a widely
used animal model of obesity and type 2 diabetes. These animals
display insulin resistance, dyslipidemia, hyperinsulinemia [30,31]
and, in some colonies, hypertension develops by 4–5 months of
age [32].
Six-weeks old male ZDF rats were injected with either CB3
(1 mg/kg and 10 mg/kg) or with Rosiglidasone (Rosi) for 28 days.
Blood glucose was measured every week (glucometer). At day 26
an OGTT assay was obtained and measured. At day 28, the animals
were sacriﬁced and different biochemical blood markers (Table 1)
were measured. Animal brains were collected, homogenized and
quantiﬁed for protein content. The samples from these animals
were separated by SDS-PAGE and analyzed by western blot as
described.
Western blot analysis
Twenty to thirty micrograms of protein samples were loaded
on 10–12% SDS-PAGE gels. The proteins were then transferred
electrophoretically to nitrocellulose (Whatman, Germany). The
blots were blocked by incubation for 1 h at RT in TBS-T (25 mM
Table 1
Weekly analysis of blood glucose levels, OGTT measurement at day 26, HbA1c blood levels, triglyceride blood levels, insulin blood levels and NEFAs blood levels at day 28.
Parameter Saline (Zucker) CB3, 1mg/kg CB3, 10 mg/kg Rosi, 10 mg/kg
HbA1c (%) 7.2470.56 7.4970.51 9.5470.85 4.5670.05*
Triglyceride (mg/dl) 873.5751.4 881.7740.7 1065.07147.8 112.477.07*
NEFAs (mEq/L) 0.6170.06 0.5870.06 0.4770.08 0.1470.03*
Insulin (ng/ml) 13.572.9 18.672.9 13.472.6 6.572.1
MCP-1 (pg/ml) 68457587 55327834 53617786 53077874
The values shown are the averages (7SEM) of all animals in each group. Student0s t-test (two populations) was performed for ZDF rats treated with saline only (Zucker).
n P valueo0.05; (n¼4–8).
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Tris–HCl pH 7.4, 0.9% NaCl and 0.02% Tween-20) with 4% Difco
skim milk (BD, USA), and incubated over-night at 4 1C with the
primary antibody: pERK1/2 (Thr 202/Tyr204), mouse mAb; ERK2
(Santa Cruz, U.S.A) rabbit Ab; p-SAPK/JNK (Thr183/Tyr185), rabbit
mAb; SAPK/JNK, mouse mAb; p-p38MAP kinase (Thr180/Tyr182),
rabbit mAb; p38, rabbit Ab; cleaved caspase 3, rabbit mAb; PARP
(Poly (ADP-ribose) polymerase), rabbit Ab; GAPDH (glyceralde-
hyde 3-phosphate dehydrogenase), rabbit mAb; TXNIP/TBP-2
mouse mAb. Antibodies were from Cell Signaling Tech. USA, if
not otherwise stated, used at 1:1000. Puriﬁed b Catenin, mouse
mAb, (1:10,000; BD Transduction Laboratories, USA) diluted in 5%
BSA, 0.04% azide in TBS-T. Proteins were detected with anti-mouse
or anti-rabbit IgG-HRP linked antibody (1:10,000; Cell Signaling,
Tech. USA). For data analysis, the amounts of each band were
quantiﬁed by using the EZ-Quant software (version 2.2) and
plotted with a linear regression program.
Results
CB3 had no effect on blood glucose or insulin content levels
We used ZDF rats characterized by a progressive β-cell
dysfunction and a leptin receptor defect, which result in hyper-
glycemia. The ZDF rats were divided into 4 groups. Animals were
i.p. injected with vehicle (0.9% saline), 1 mg/kg CB3, 10 mg/kg CB3,
or p.o. with 10 mg/kg rosiglitazone (Rosi), an antidiabetic agent,
which activates peroxisome proliferator-activated receptor gamma
(PPAR-γ agonist). Blood glucose levels and plasma insulin were
tested as indicated (Table 1). Rats treated with Rosi displayed a
signiﬁcant decrease in blood glucose and plasma insulin levels
compared to the control group. In contrast, CB3 had no effect on
either blood glucose or plasma insulin in the groups compared to
the saline supplemented animals (Table 1).
CB3 lowered MAPK JNK and p38 phosphorylation, but not MAPK
ERK1/2 in brain of ZDF rats
To explore whether CB3 protected the ZDF rat brain from the
effects of high glucose, we monitored the inﬂammatory state of the
brain analyzing the phosphorylation level of three kinases, c-Jun
NH2-terminal kinase (JNK), p38 MAP kinase (p38MAPK) and the
extracellular-signal-regulated kinases 1 and 2 (ERK1/2). Rats injected
with 1 mg/kg of CB3 showed no signiﬁcant change in p38MAPK, JNK,
or ERK1/2 phosphorylation compared to the untreated group. In
contrast, the phosphorylation level of both p38MAPK and JNK was
signiﬁcantly lowered in animals treated with 10 mg/kg CB3 or with
10 mg/kg Rosi (Fig. 1A and B). The reduction by CB3 suggests a
speciﬁc effect of the Trx1 mimetics, which by increasing the ratio of
Trx1re/Trx1ox, prevented Trx1–ASK1-dissociation, and inhibited the
Trx1–ASK1–MAPK pathway [27]. The signiﬁcant decrease in JNK and
p38MAPK phosphorylations in the Rosi-treated rats most probably
was secondary to PPARγ-mediated changes in metabolism.
ERK1/2 is activated by intracellular accumulation of free radicals
and involves another inﬂammatory cascade [33,34], independent of
the ASK1–Trx1 pathway. Therefore it was expected to be less sensitive
to CB3. Indeed, no signiﬁcant reduction in ERK1/2 phosphorylation
was observed in the CB3 treated animals (Fig. 1C). Given Rosi reduced
glucose in plasma and CB3 did not, these data suggest that the
changes in ERK1/2 may be secondary to altered fuel metabolism.
Fig. 1. CB3 inactivates JNK and p38 but not ERK1/2 in the brains of ZDF rats. ZDF rats were supplemented with either CB3 or Rosi for 28 days (as described in Table 1). Brain
samples of each animal from each group were homogenized and proteins were separated by SDS-PAGE (Section 2). The blots were incubated with antibodies against
(A) p38MAPK phospho-p38MAPK and β-catenin (B) JNK and phospho-JNK or (C) ERK1/2 and phospho-ERK 1/2. Each band represents a single animal of each group. The values
were quantiﬁed shown as the averages (7SEM) of all the bands presented in the blots (right). The values were normalized to the phosphorylation state of ZDF rats treated
with saline only (Zucker). Student0s t test (two populations) was performed for ZDF rats treated with saline only (Zucker). *P valueo0.05; **P valueo0.01; and
***P valueo0.005, (n¼4–8).
M. Cohen-Kutner et al. / Redox Biology 2 (2014) 447–456 449
The TxM-mimetics, CB3 and CB4, prevent MAPK induction by blocking
thioredoxin reductase or by TNFα
We next examined the consequences of CB3 on inﬂammatory
pathways induced in SH-SY5Y cells, a human neuroblastoma cell
line often used as a cellular model of AD. In addition we used CB4,
another member of the thioredoxin-mimetic family TxM-CB4
(NAc-Cys-Gly-Pro-Cys amide), which was previously shown to be
effective in reversing amyloid beta-induced protein oxidation, loss
of mitochondrial function and DNA fragmentation in primary
neuronal cells [29]. CB4 was also effective in reversing oxidaitve
stress-induced apoptosis in PC12 [26], and insulinoma cells [27].
We monitored p38MAPK and JNK phosphorylation/activation
induced by exposure of the cells to auranoﬁn (AuF), a potent TrxR
inhibitor. By keeping Trx1 in the oxidized-state, AuF leads to the
dissociation of oxidized Trx1 from ASK1, activating the ASK1–
MAPK cascade [5]. SH-SY5Y cells were treated for 30 min with
5 mM AuF, washed and incubated for 2 h with or without CB3 or
Fig. 2. CB3 and CB4 reverse the phosphorylation of JNK and p38MAPK but not ERK1/2 in SH-SH5Y cells. SH-SY5Y cells were treated with 5 mM AuF for 30 min, washed, and
treated with or without increasing concentrations of CB3 and CB4, as indicated. Cell lysates were separated by SDS-PAGE and the phosphorylation of (A) JNK (B) p38MAPK or
(C) ERK1/2 were visualized by immunoblots using the appropriate antibodies (see above) and quantiﬁed (right). The values are averages (7SEM) of three independent
experiments normalized to the phosphorylation state of cells treated with AuF. (D) Cells treated with 5 ng/ml TNF-α, with or without CB3 (100 mM) at the indicated time
intervals. Equal amounts of whole-cell lysates were separated on SDS-PAGE and JNK phosphorylation was determined by immunoblots (left) and quantiﬁed (right).
The values are averages (7SEM) of three independent experiments normalized to control cells. Student0s t test (two populations) was performed for AuF/TNF-a treated cells.
*P valueo0.05; **P valueo0.01; and ***P valueo0.005.
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CB4 at the indicated concentrations. The phosphorylation of MAPK
was monitored by western blot analysis using selective antibodies
against phosphorylated p38MAPK, JNK, and ERK1/2, and the corre-
sponding non-phosphorylated MAPKs (Fig. 2A, B and C). The
reduction of AuF-induced JNK and p38MAPK phosphorylation was
concentration-dependent (Fig. 2A and B). CB3 and CB4 were
considerably more effective in reducing AuF-induced JNK and
p38MAPK phosphorylation (Fig. 2A and B) compared to the AuF-
induced ERK1/2 phosphorylation (Fig. 2C). This result is consistent
with the lack of any signiﬁcant effect of CB3 on ERK1/2 phosphor-
ylation in the ZDF brain (Fig. 2C). This speciﬁc inhibition of JNK
and p38MAPK phosphorylation by TxM, further supports the view
that the Trx1 mimetics act through preventing ASK1–Trx1
dissociation
Further evidences for the anti inﬂammatory effects of the TxM
peptides were achieved by examining TNFα, a ROS-independent
inﬂammatory reagent known as a JNK activator [35]. SH-SY5Y cells
were exposed to 5 ng/ml TNFα with or without CB3 (100 mM) for
10, 20 and 30 min. At these time intervals JNK activation was
signiﬁcantly reduced by CB3, further supporting the anti-
inﬂammatory effects of CB3 (Fig. 2D).
CB3 reduces TXNIP/TBP-2 levels in the brain of ZDF rats
Next we explored the expression and the impact of CB3 on the
expression of TXNIP/TBP-2 in the ZDF rat. As shown in Fig. 3A, a
signiﬁcant reduction in TXNIP expression was observed in the
brain of animals treated with 10 mg/kg of CB3, but not with 1 mg/kg.
In contrast, in the Rosi-treated rats no signiﬁcant reduction in TXNIP/
TBP-2 expression was observed, in spite of a strong reduction in
blood glucose. These results suggest that the Trx mimetic peptide
most probably lowers an intrinsically high level of TXNIP/TBP-2 in the
ZDF rats independent of blood glucose. Further studies are required
to explore the nature of the glucose dependency of the elevated
levels of TXNIP/TBP-2 in the ZDF rat brain.
Unlike the high glucose up-regulation of TXNIP/TBP-2 in beta
cells [36], high glucose in neuronal SH-SY5Y cells had no apparent
effect on TXNIP/TBP-2 expression (data not shown). CB3 (100 mM)
appeared to cause a substantial reduction in the constitutive
TXNIP/TBP-2 expression in these cells (Fig. 3B).
Adenosine-mono phosphate (AMP) activated protein kinase (AMPK)
is activated in the brain of CB3 treated ZDF rats
The anti-diabetic drugs, Rosi and metformin are known as
activators of the AMPK pathway, which reduce intracellular ATP by
inhibiting complex I of the mitochondrial electron transport chain
[37]. Therefore, we measured the AMPK alpha Thr172 phosphor-
ylation in the brain of ZDF rats that were treated with 10 mg/kg
Rosi, 1 mg/kg, and 10 mg/kg of CB3. As expected, Rosi-treated
animals showed almost a two-fold increase in AMPK activation
(Fig. 4A). Surprisingly, AMPK was equally activated in the brain of
1 or 10 mg/kg of CB3 injected ZDF rats.
The phosphorylation level of AMPK, which leads to inhibition
of the mammalian target of rapamycin (m-TOR) pathway, was
further evaluated in the ZDF brain. AMPK mediates m-TOR inhibi-
tion through binding of Raptor and phosphorylation of p70S6
kinase, a protein involved in numerous cell-signaling pathways.
We observed that in both CB3 and Rosi treated animals phosphor-
ylation of p70S6 kinase in the ZDF brain was reduced (Fig. 4B).
These results suggest that AMPK activation by CB3 led to the
inhibition of the downstream AMPK–m-TOR-signaling, similar to
the effect of Rosi.
CB3 and CB4 protect SH-SY5Y cells from AuF toxicity
The effects of AuF on cell viability and the protection offered by
CB3 and CB4 were visualized and quantiﬁed in SH-SY5Y cells.
The cells were treated with AuF (5 mM) for 30 min, washed, and
visualized 24 h later. Phase contrast microscopy demonstrated a
considerable change in cell morphology and cell number (Fig. 5A).
In contrast, most of the CB3- or CB4-treated cells appeared healthy
under phase-contrast microscopy, showing normal shape and
well-developed cell to-cell contact (Fig. 5A). The decrease in cell
Fig. 3. CB3 reduces TXNIP/TBP-2 levels in the brain of ZDF rats and in SH-SY5Y cells. ZDF rats were supplemented with either CB3 or Rosi for 28 days as indicated in Fig. 1.
Brain samples were lysed and proteins were separated on SDS-PAGE (A) left, TXNIP/TBP-2, levels were determined using TXNIP/TBP-2 antibodies using anti GAPDH
antibodies as a reference. Right, all values of each group were collected and normalized to GAPDH. (B) SH-SY5Y cells were exposed to increasing concentrations of CB3, as
indicated. The level of TXNIP/TBP-2 was determined using anti TXNIP antibodies (left), and the data was quantiﬁed using GAPDH as a reference (right). The results represent
the averages (7SEM) of all the bands presented in the blots. All values were normalized to the TXNIP/TBP-2 levels of ZDF rats treated with saline only (Zucker) or to the
levels of control cells. Student0s t test (two populations) was performed for ZDF rats treated with saline only (Zucker) or to control cells. *P valueo0.05; **P valueo0.01; and
nnnP valueo0.005, (n¼4–8).
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viability by AuF (1–10 mM) was quantiﬁed using the methylene
blue viability assay (see Section 2) [27]. After 24 h the number of
viable cells was signiﬁcantly increased in the presence of 100 mM
CB3 at all AuF concentrations (Fig. 5B). Rescue from 5 mM AuF
toxicity was also seen in cells treated with CB4 in a concentration
dependent manner (Fig. 5C).
CB3 and CB4 inhibit caspase 3 and PARP dissociation
in SH-SY5Y cells
Next we tested the effect of CB3 on caspase 3-cleavage in SH-
SY5Y cells. The cells were incubated with 100 mM CB3 for 24 h in
serum-free medium. A reduction in caspase 3-cleavage was observed
in CB3 treated cells in a concentration dependent manner, seen
already at 50 mM (Fig. 6A). We then examined the nuclear enzyme
poly (ADP-ribose) polymerase (PARP), which is constitutively
expressed in the cell and stimulated allosterically by DNA single-
strand breaks that are generated during a redox injury [38]. During
apoptosis PARP is dissociated by caspase 3 and loses its activity to
induce necrosis [30]. Treatment with 5 mM AuF increased PARP
dissociation consistent with the viability assays (Fig. 5). A consider-
able decrease in PARP dissociation was observed in AuF-treated cells
that were exposed to CB3 or CB4 (Fig. 6B). These results further
conﬁrm the anti-apoptotic properties of TxM peptides [26], [27].
Fig. 4. CB3 increases AMPK activation and inhibits p70S6 kinase in the brains of ZDF rats. ZDF rat brain samples were separated by SDS-PAGE as described. The blots of each
group, were incubated with antibodies against (A) AMPK, and pAMPK and (B) p70S6K, and phospho p70S6K. Each band represents a single animal in each group. The data
was quantiﬁed (right) represent averages (7SEM) of three independent experiments. The values were normalized to the ZDF rats treated with saline only (Zucker). Student0s
t test (two populations) was performed for ZDF rats treated with saline only (Zucker). *P valueo0.05; **P valueo0.01; and ***P valueo0.005, (n¼4–8).
Fig. 5. TXM peptides -CxC- and -CxxC- protect SH-SH5Y cells from AuF-induced cell death. (A) Phase-microscope images of SH-SY5Y cells treated with AuF and with CB3 or
CB4, taken after 24 h (magniﬁcation, 100). (B) The cells were incubated with increasing concentrations of AuF for 30 min, washed and incubated with or without CB3
(100 mM). The cells were tested for viability using the methylene blue assay after 24 h (C) Viability of cells pre-treated with 5 mM AuF, washed and later exposed to increasing
concentrations of CB4, was determined 24 h later. Data is displayed as mean7S.E.M (n¼8–12). Student0s t test (two populations) was performed for AuF treated cells.
*P valueo0.05; **P valueo0.01; and ***P valueo0.005.
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Discussion
In this study we analyzed the protection of ZDF rat brain and
human SH-5Y5Y neuroblastoma cells from oxidative induced
inﬂammation damages and from inﬂammatory consequences
accompanying diabetes or through disruption of the TrxR–Trx
redox system. For this purpose we used the thioredoxin mimetic
peptides, CB3 and CB4. These peptides derived from the canonical
CxxC motif of the Trx1 active site and a modiﬁed CxC motif, which
are responsible for the redox activity of Trx1.
CB3 inhibits MAPK phosphorylation in ZDF rat brain
The TxM thiol peptides alleviate oxidative stress by inhibiting
JNK and p38MAPK phosphorylations and preventing NF-kB nuclear
translocation in vitro and in vivo [26–29]. It was shown that
obesity increases cerebrocortical ROS and impairs brain function
[39]. Diabetes is also a signiﬁcant risk factor for dementia in
general, including AD, and probably vascular dementia [40]. Diet-
ary fat intake was shown in epidemiological studies to increase the
risk of incident dementia [41] and decrease Morris maze perfor-
mance [42]. This further conﬁrms the role of high glucose in
destructing brain function. The anti-inﬂammatory and anti-
apoptotic properties of TxM peptides could prove to be useful in
relieving oxidative stress elicited in the brain of obese rats, which
led us to test CB3 in the ZDF brain.
Here we tested inhibition by CB3 of inﬂammatory pathways
that are activated by MAP-Kinases, JNK and p38, in the ZDF rat
brain. Although no changes in blood glucose were observed, the
CB3 treated mice displayed a decrease in the phosphorylation/
activation of the MAPK inﬂammatory-stress pathway with its
ensuing apoptotic effects. Although the decrease in phosphorylated
JNK and 38MAPK in the brain might indicate that CB3 crosses
the blood brain barrier (BBB) in order to protect against inﬂam-
matory neurodegenerative consequences in the ZDF rats, more
direct studies are required to establish BBB penetration of TxM
peptides.
Interestingly, in previous studies N-acetyl cysteine (NAC),
which is a much weaker reducing reagent compared to CB3 [26],
resulted in a signiﬁcant reduction in blood glucose of the ZDF rat
[22], [43]. The decrease in plasma glucose by NAC, which became
apparent at the 9th week [22,43] suggest that to ascertain
reduction in blood glucose it would be important to monitor
blood glucose in CB3-treated ZDF rats over a longer period
compared to the present study [22]. The lower level of MAPK
phosphorylation in the Rosi-treated rats could be attributed in
part, to its ability to prevent glucose increase, or to a PPAR-speciﬁc
effect. Rosi was demonstrated to attenuate endotoxin lethality by
inhibiting HMGB1 release in a mouse model of sepsis [18].
In studies carried out using insulinoma cells, CB3 appeared to
prevent apoptosis through inhibiting the Trx1–ASK1–MAPK path-
way [27]. Protection of the ZDF rat brain from the inﬂammatory
damage is consistent with TXM antiapoptotic affects seen also in
the neuroendocrine PC12 [26] and insulinoma cells [27].
TxM-peptides rescue SH-5HSY cells from apoptosis
Human neuronal SH-5Y5Y cells are often considered a model
for Alzheimer0s disease. These cells, when treated with CB3 or CB4,
displayed protection from oxidative stress induced by blocking the
[TrxR–Trx] redox system. The increase in cell viability, which was
accompanied by a decrease in caspase-3 cleavage, prevention of
PARP dissociation, as well as the ability to reverse TNF-alpha
induced JNK phosphorylation in SH-SH5Y cells, further supports
Fig. 6. CB3 and CB4 inhibit caspase 3 and PARP dissociation in SH-SY5Y cells. (A) SH-SY5Y cells were treated for 24 h with or without CB3 at the concentrations as indicated.
Equal proteins of whole-cell lysates were separated by SDS-PAGE. Caspase 3 cleavage was detected using antibodies against cleaved caspase-3. (B) Increasing concentrations
of CB3 or CB4 were tested for preventing AuF-induced PARP dissociation. PARP dissociation was detected using antibodies against PARP. The values were quantiﬁed as shown
(right) are averages (7SEM) of three independent experiments. Student0s t test (two populations) was performed for either control or AuF treated cells in B. *P valueo0.05;
and ***P valueo0.005.
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the anti-inﬂammatory properties of these peptides. TxM putative
activity pathway is shown schematically in Fig. 7. Consistent with
the in vivo ZDF data, these results suggest that inhibiting the TRX–
ASK1–MAPK pathway, which is accompanied by an increase in
AMPK, could protect rat brain neuronal cells from apoptosis and
implicate a potential use of this Trx1 mimetic peptide for treating
inﬂammation induced by high glucose. The in vivo and in vitro
data is consistent with TXM proposed activity previously shown
using insulinoma 832/13 cells [27].
CB3 lowers TXNNI/TBP-2 expression in ZDF rat brain
TXNIP/TBP-2 is a key stress-responsive inhibitory switch of Trx1
activity playing an important role in the preservation of cellular
viability [44]. Recent knockout studies, suggested that inhibition of
TXNIP/TBP-2, up regulates both insulin sensitivity and glucose-
stimulated insulin secretion in diabetes, and might present a novel
therapeutic approach for T2DM [13,45]. Also in humans, TXNIP/TBP-2
was shown to regulate peripheral glucose [46].
We observed a signiﬁcant decrease in TXNIP/TBP-2 levels in
CB3 treated ZDF rats. The mechanism by which CB3 lowers TXNIP/
TBP-2 currently remains unknown. It is possible that by lowering
ROS, CB3 prevents TXNIP/TBP-2 up regulation through inhibiting
transcription. This possibility is consistent with a recent study
demonstrating that TXNIP/TBP-2 expression in the brain was
induced by oxidative stress without glucose [15]. Consistent with
the results of Trx1 over expression, which was shown to be
neuroprotective against ischemic brain damage [47], the Trx1
mimetic CB3 appeared to dramatically prevent oxidative stress
damages by lowering MAP kinase activity as well as TXNIP/TBP-2
expression in the ZDF brain. Alternatively, by reducing the dis-
ulﬁde bridge between Cys32/Cys35 and TXNIP/TBP-2, CB3 induces
TXNIP/TBP-2 dissociation from Trx1. The Trx1-free-TXNIP/TBP-2 in
turn, inhibits TXNIP transcription, down regulating the transcrip-
tionally activated carbohydrate response element-binding protein.
In the Rosi-treated animals, in which glucose and triglycerides
levels were low, TXNIP/TBP-2 level was not decreased. In contrast,
in CB3-treated animals in which glucose and triglycerides levels
were high, altering of the Trx/TXNIP redox balance, CB3 appeared
to regulate TXNIP/TBP-2 in a glucose independent mechanism.
Unlike a strong induction of TXNIP/TBP-2 by high glucose in
insulinoma cells [48], the level of TXNIP/TBP2 in SH-SY5Y cells was
constitutively high and was not induced further by high glucose.
The TXNIP/TBP-2 level, which was lowered by CB3 and CB4, could
result from an oxidative stress other than glucose. These results
underline the possibility that an improvement in the redox state of
SH-SY5Y cells by Trx-mimetic peptides could decrease TXNIP/TBP-
2 transcription.
CB3 activates AMPK
The involvement of AMPK in diabetes was reported in previous
studies [31,49,32]. AMPK activation promotes glucose uptake and
removal from the periphery [50]. Metformin, an activator of AMPK,
markedly inhibits TXNIP/TBP-2 mRNA and protein expression. It
was suggested to function by inhibiting complex I in the mito-
chondrial respiratory system, partially via AMPK [51,31], and
through regulation of TXNIP/TBP-2 transcription [49]. AMPK
activity is diminished in the muscle and/or liver of ZDF rats.
Treatment with the AMPK activator (AICAR) prevented the devel-
opment of diabetes, and an increase in triglyceride content in liver,
muscle and pancreatic islets [52]. Furthermore, pancreatic β-cell
morphology was almost normal in AICAR-treated animals, indicat-
ing that chronic AMPK activation in vivo might preserve β-cell
function [53].
Here we show that in the ZDF brain phosphorylated AMPK was
signiﬁcantly elevated in both CB3- and Rosi-treated rats. To our
knowledge, this is the ﬁrst study demonstrating AMPK activation
by a Trx1 mimetic peptide. The increase in AMPK phosphorylation
in the brain of CB3 treated ZDF-rats, was in good correlation with a
decrease in TXNIP/TBP-2 expression and subsequent blocking of
the phosphorylation of p70S6K through the mTOR–p70S6K path-
way (Fig. 7).
In the Rosi-treated rats AMPK phosphorylation was signiﬁ-
cantly increased as expected; however, no apparent reduction in
TXNIP/TBP-2 was observed. Further studies are needed to explore
why repression of TXNIP/TBP-2 transcription, shown by metfor-
min [31], was not observed in the ZDF brain of Rosi-treated rats.
In summary, in the present 28 days-term experiment the
thioredoxin mimetic peptide CB3, attenuated p38MAPK and JNK
activity, diminished TXNIP/TBP-2 over expression, and activated
AMPK in the brain of ZDF rats. The anti inﬂammatory effects of CB3
in the brain of the ZDF rat were mediated through the MAPK-
AMPK-mTOR-p70SP6 signaling pathway. CB3 displayed these pro-
tective effects without reducing glucose triglyceride levels or
insulin indexes, as opposed to Rosi-treated ZDF rats, in which
the decrease in glucose triglyceride levels or insulin indexes
account for the decrease in the neuro-inﬂammatory signaling.
The signiﬁcant decrease in TXNIP/TBP-2 expression in the brain
was observed only in the CB3- and not in the Rosi-treated rats.
This is the ﬁrst study that demonstrates signiﬁcant protective
effects by a Trx1 mimetic peptide in the brain of diabetic animals.
We suggest that the reduction in the activation of the stress
signaling in the brain could lower the risk factor for an accelerated
rate of cognitive decline and memory impairments associated with
diabetes..
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